Academic institutions studying outcomes research, pharmacology, and pharmacoepidemiology work with us to bolster existing projects and support the launch of new studies of drug safety issues in pipeline and approved drugs. Our peer reviewed analytic tools give our research partners a major advantage in being able to quickly identify emerging safety and costing issues for further study.
Most of our clients have tried to work with raw safety data or open-sourced solutions to no avail. By partnering with Advera Health, they gain access to curated, annotated data that has been optimized with our peer reviewed data aggregation and cleansing methodology. They also gain access to our peer reviewed analytic tools that quickly speed the time to test existing hypotheses and develop new ones.
The Advera Health team has been working with clinical and real world safety data for years. Our expert analyst staff works in partnership with our academic clients on posters and publications, helps direct internal academic staff on best practices, and helps speed the research process. With a strong publication history of our own, our team knows how to get the most out of your research goals.
Researchers at the Epidemiology, Biostatistics and Prevention Institute at the University of Zurich were struggling to compare disproportionality safety signals from FAERS to adverse event risk estimates from randomized trials included in Cochrane systematic reviews. In order to assess whether a correlation exists between these two methodologies, the Zurich team needed a source for cleaned, de-duplicated, and dynamically linked FAERS Data to ensure harmonized processes and reliable data analysis. They leveraged Advera’s FAERS Data and our highly trained data analyst team to quickly complete their research and successfully present their findings at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management.